


HUMALOG "MIX" UPS

The Lilly range of insulin has expanded – two new premixed preparations have been added to the range: Humalog Mix25[®] and Humalog Mix50[®]. These preparations contain a mixture of rapid-acting insulin and intermediate-acting insulin. While the cartridges are very similar in appearance to the rapid-acting insulin Humalog[®], they are clinically different. Errors have occurred when prescribing, selecting and administering these insulins.

This POSTER highlights the different preparations, the action profile of each formulation and identifies ways to reduce the risk of incidents occurring.

HUMALOG[®] insulin is RAPID-ACTING



Rapid-acting insulin is clear

Brand Name ^{2,3}	Type of Insulin (generic name) / Product Description	Presentation	Schematic Action Profile ⁴
Humalog[®]	insulin lispro Rbe RAPID-ACTING	10mL vials and 3mL cartridges	 <p>Onset: 0–15 mins ● Peak: 1 hour ○ Duration: 3.5–4.5 hours</p>



HUMALOG MIX[®] insulin is INTERMEDIATE-ACTING

Premixed insulin is cloudy

Humalog[®] Mix25[®]	25% insulin lispro, 75% insulin lispro protamine suspension Rbe PREMIXED INSULIN LISPRO	3mL cartridges	 <p>Onset: 0–15 mins ● Peak: 1 hour ○ Duration: 16–18 hours</p>
Humalog[®] Mix50[®]	50% insulin lispro, 50% insulin lispro protamine suspension Rbe PREMIXED INSULIN LISPRO	3mL cartridges	 <p>Onset: 0–15 mins ● Peak: 2 hour ○ Duration: 16–18 hours</p>



SAFE PRACTICE RECOMMENDATIONS

- § Prescribe insulin using the FULL BRAND name; prescribe UNITS in FULL
e.g. Humalog[®] (insulin lispro) 10 units or Humalog Mix25[®] (premixed insulin lispro) 22 units
- § Familiarise yourself with the dosing schedules for the different Humalog[®] products
- § When using electronic prescribing or dispensing systems – cross check you have selected the right product from the drop down menu
- § Double check the vial or cartridge against the prescription every time you administer insulin
- § When prescribing, dispensing or administering check what type of insulin the patient should be on and confirm "type" with the patient
- § Highlight to patients' prescribed Humalog or Humalog Mix the potential confusion

Disclaimer: These recommendations are based on a review of the currently available information in order to assist practitioners. The recommendations are general guidelines only and are not intended to be a substitute for individual clinical decision making in specific cases

SQM Group would like to thank the pharmacy department, Capital and Coast DHB for developing this poster and allowing DHB NZ SQM Group to use the content

Published April 2010